More foreign capital key to the future of Switzerland as an innovation location

27 January 2025

Israel – a country that receives almost half of its research and development investments from foreign capital – is a striking example of how international financing can contribute to the strength of an innovation ecosystem, according to a posting on the website of Swiss pharma trade group Interpharma.

Switzerland, on the other hand, only receives 6% of its R&D investments from foreign sources. Interpharma said a comparison that raises questions is: Could more international capital also strengthen Switzerland as an innovation location?

Israel's success model: A focus on global markets

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical